Single‐ and multiple‐dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects

@article{Sidharta2014SingleAM,
  title={Single‐ and multiple‐dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects},
  author={P. Sidharta and Z. Diamant and J. Dingemanse},
  journal={Fundamental & Clinical Pharmacology},
  year={2014},
  volume={28}
}
  • P. Sidharta, Z. Diamant, J. Dingemanse
  • Published 2014
  • Medicine
  • Fundamental & Clinical Pharmacology
  • Chemoattractant receptor‐homologous molecule expressed on T helper (Th) 2 cells (CRTH2) is a G‐protein‐coupled receptor for prostaglandin D2 (PGD2), a key mediator in inflammatory disorders such as asthma and allergic rhinitis. In this study, we investigated the single‐ and multiple‐dose tolerability and pharmacokinetics (PKs) of setipiprant, an orally active, potent, and selective CRTH2 antagonist. This randomized, double‐blind, placebo‐controlled study was performed in two parts in healthy… CONTINUE READING
    11 Citations
    Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
    • 40
    • PDF
    Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies
    • 14

    References

    SHOWING 1-10 OF 41 REFERENCES
    Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist
    • 49
    Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    • 76
    Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
    • 81
    • PDF
    Prostaglandin D₂ receptor CRTH2 antagonists for the treatment of inflammatory diseases.
    • 19
    Novel CRTH2 antagonists: a review of patents from 2006 to 2009
    • 48
    CRTH2 expression on T cells in asthma
    • 41